William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses predictors of overall outcomes and survival in patients with ovarian cancer.
William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses predictors of overall outcomes and survival in patients with ovarian cancer.
Transcript
What are the predictors of surgical outcomes that you have identified in ovarian cancer?
So, we’ve looked at, both nationally and within our own institution at Mayo Clinic, factors that predict outcomes in ovarian cancer. So, overall outcomes are predicted by things like the volume of the operating center, so how many patients with ovarian cancer did they take care of. The next biggest one is adherence to national guidelines; the National Comprehensive Cancer Network guidelines for how to manage ovarian cancer. Both of those are very important for overall outcomes, and I’m talking about survival in ovarian cancer. So, patients are better served by being cared for in expert centers that adhere to these guidelines.
More specifically, when we’ve looked at our own institutional data, what we observe is that outcomes that predict overall survival best are things like patient factors: their underlying health, what stage of cancer do they show up with. But, then the things we can control, like surgical outcomes, such as amount of residual disease, is very important for overall survival in ovarian cancer.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More